Price Vision Group Participating in Clinical Study of Investigational Growth Factor Treatment for Eye Disorder, Fuchs Endothelial Corneal Dystrophy

March 10, 2021 by Admin9

Indianapolis, IN – March 10, 2021 – Price Vision Group announced today that it is the first site to initiate patient treatment in a clinical trial evaluating use an experimental drug treatment in conjunction with a surgical procedure that treats the back surface of the cornea to restore vision in patients with a condition called Fuchs Endothelial Corneal Dystrophy (FECD).  More than four percent of the population over the age of 40 is at risk of developing FECD and this disease is the leading cause of corneal transplantation in the U.S.

FECD results from the loss of specific cells (endothelial cells) that line the back of the cornea, over time this leads to cloudy vision and potentially blindness. The clinical trial is being conducted in FECD patients who are already planning to undergo a surgical procedure, referred to as DSO (Descemet Stripping Only) or DWEK (Descemetorhexis without Endothelial Keratoplasty).  This procedure removes diseased cells and the collagen bumps (guttae) they produce from a central area of the cornea. Normal cells then repopulate the area over time to improve vision. The clinical trial will evaluate whether administering an experimental drug, TTHX1114 (an engineered form of a natural protein called FGF-1) can accelerate and enhance the visual recovery process. Patients participating in the clinical trial will have the option to receive TTHX1114 in addition to DSO surgery or to receive DSO surgery alone.

“The Price Vision Group strives to provide state of the art care to our patients,” said Dr. Francis Price, founder of the practice. “DSO is an innovative new procedure that provides an alternative to corneal transplantation. As a provider of the DSO procedure, we are excited to participate as one of the sites in the U.S. in this clinical trial of TTHX1114.”

About FECD and corneal endothelial disorders

Corneal endothelial cells line the interior of the cornea and are critical to maintaining its appropriate hydration state, which enables the cornea to function properly. FECD, the most common corneal endothelial disorder, is the leading cause of corneal transplantation/graft in the U.S.

The hallmark of FECD is excessive loss of endothelial cells and the formation of collagen bumps (guttae), resulting in diminished vision and, in severe cases, blindness. Loss of these cells is also a contributor to poor outcomes in eye surgery, including cataract surgery.

Although transplant surgery with human donor corneas has been shown to be effective in restoring vision for many FECD patients, most patients require long‑term immune suppression therapy which can have unintended side effects. DSO, which has been developed as an alternative to corneal transplants, does not require donor tissue and therefore eliminates the need for immune suppressive drugs.

About TTHX1114

TTHX1114 is an engineered form of the naturally occurring molecule Fibroblast Growth Factor-1 (FGF-1), which stimulates cell proliferation and migration as well as protects cells from stress and injury. TTHX1114 has been engineered to increase FGF-1’s longevity in the eye, enabling its use as a pharmaceutical. The study is sponsored by San Diego-based Trefoil Therapeutics, a private biotechnology company developing therapeutics for corneal diseases.

About Price Vision Group

Price Vision Group is a d/b/a of Corneal Consultants of Indiana, P.C., an internationally recognized center for the diagnosis, treatment, and care in the field of corneal and refractive surgery. We, along with our research partner, Cornea Research Foundation of America, have conducted more than 160 studies including those that led to the FDA approval of LASIK.

For more than 30 years, The Price Vision Group has utilized the latest technology while conducting ground-breaking research to provide cutting-edge services to patients from all over the world.

In addition to training over 600 doctors from around the world, Price Vision Group surgeons have performed more cornea transplants than any other practice in North America. As some of the world’s foremost experts in corneal care, Price Vision Group are sent some of the most challenging surgical cases based on their expertise and experience with complex corneal procedures.




Marianne Price, Ph.D.
Executive Director
Cornea Research Foundation of America



Robert Gottlieb
RMG Associates, LLC


  • janene a emswiller

    March 19, 2021 at 9:40 pm

    Best to text me, because I don’t answer calls without a name. Too many spam calls, is why. My email, I will check, if you text me, that you sent me an email. Otherwise it’s just checked, maybe once in awhile.
    Looking for opinions, because I don’t know what I’d need for sure.


    • Susan Boot

      August 13, 2022 at 12:29 pm

      I have been diagnosed with Fuchs endothelial dystrophy and just recently been sent to see a specialist for cataract problem. He has suggested leaving for a while and managing without. My problem is I don’t know which is the better option. To leave operation or not. Just very worried.


  • Louis Goglia

    August 27, 2021 at 2:08 pm

    I’m interested in obtaining more information. Currently being treated at VA Hospital in Atlanta for glaucoma in right eye. Diagnosed 6 months ago with Fuchs disease. Starting losing sight in right eye in February. Want to know if your procedure would benefit me.


  • Michael Rickman

    November 2, 2021 at 7:26 am

    I have been admitted to an Eye hospital in San Diego to set up a TTHX1114 function on my cornea. After successful operation, I have realized that it stimulates my cell proliferation and protects my eyes from stress and injury. And it also increases FGF-1’s longevity in my eyes. Thanks a lot for your informative blog!


  • Ophir Toledo

    December 10, 2021 at 2:44 pm

    Fantastic news: cure FECD without surgery will be a relief for 400 million sufferers around the world that today are having life disrupted due to this disease.
    I was diagnostic with FECD 20 yrs ago when it still had not affected my vision. It has gotten worse in the last 5 yrs to the point no lenses prescription will work and it is becoming increasingly difficult to get a good vision. I live near Miami, FL and would appreciate your referral for a doctor/clinic that is up to date with the work and processes you described. Thank you very much and God bless you all.


  • Dorothy Sherman

    December 26, 2021 at 5:23 pm

    My doctor at the Medical College of Wisconsin Eye Institute told me to wait until I was almost blind to come back. I am concerned that there may be a sooner intervention so I can continue to drive and live alone. I have Fuchs in both eyes and my vision is hazy. I have cataracts also.


  • Daisy James

    July 16, 2023 at 11:42 am

    The information you have shared in this article has shed light on an important issue in ophthalmology and highlighted a promising alternative to traditional corneal transplants. It’s exciting to see how medical science continues to evolve and provide innovative solutions for improving vision and the overall well-being of patients with FECD. Thanks for sharing this informative content.


Leave a Reply

Your email address will not be published. Required fields are marked *

Price Vision Group logo horiz white

Price Vision Group is a global leader in corneal transplant, cataract surgery, keratoconus treatment, PRK and LASIK. At our center in Indianapolis, we see patients from Indiana cities including Zionsville, Fishers, Carmel, Noblesville, Avon, and Greenwood, as well as people who travel from across the U.S. and even abroad for treatment by our renowned physicians.

Copyright 2024 Price Vision Group. All rights reserved.